HealthMore in Health→
Biogen reports Phase 2 lupus win as litifilimab improves skin lesions at 24 weeks
Key Takeaways
- Biogen says litifilimab improved skin lesions after 24 weeks in a Phase 2 lupus study.
- Endpoints describes the result as a Phase 2 success for an asset Biogen hopes will become central to its immunology pipeline.
- The available source text supports a cautious read: a promising mid-stage efficacy signal, but not a final answer on late-stage success.
DE
DT Editorial Team··via endpoints.news